ClinicalTrials.gg
Active, not recruitingNCT06111209Updated Jun 26, 2026

The Anabolic Effect of Testosterone on Pelvic Floor Muscles

A Phase 2 interventional study of Testosterone cypionate and Placebo in Stress Urinary Incontinence and Menopause, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
60 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Urinary Incontinence, Stress with a site in United States — 28 open to participants now, 41 under way, 4 of them phase 3. Urinary Incontinence, Stress · United States.

Planned enrollment
129th of 164
30 · median 99
Started
2025
with 12 others
Phase 2
12 of 190
1 open now
Primary completion
2026-12
later than 16 of 40 live
Registered
164th of 190
by date

Among the 190 studies in Urinary Incontinence, Stress with a site in United States, this one is the 129th largest by planned enrollment of the 164 interventional ones that give a count, is one of 13 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 16 of the 40 other live ones, and was the 164th registered.

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

28 of the 190 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 60 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

Stress urinary incontinence is the most common female pelvic floor disorder encountered in clinical practice with significant negative impact on quality of life. The prevalence of urinary incontinence increases with aging, and weakness of the pelvic floor muscles contributes to the development of stress urinary incontinence. Given that androgen receptors are expressed throughout the pelvic floor, the anabolic effects of androgens on pelvic floor muscles may provide a therapeutic option in women with stress urinary incontinence. The investigators are conducting a randomized, double-blind, placebo-controlled proof-of-concept trial in older postmenopausal women with stress urinary incontinence to assess whether testosterone therapy can increase pelvic floor muscles and improve urinary function.

Read the detailed description

The investigators are conducting a 12-week double-blind, randomized-controlled, proof-of-concept pilot trial to determine the anabolic effect of testosterone therapy on pelvic floor muscles in postmenopausal women, 60 years and older, with stress urinary incontinence. The first aim is to compare the efficacy of testosterone supplementation versus placebo on the volume of levator ani muscles of the pelvic floor, assessed by magnetic resonance imaging (MRI). The second aim is to assess the efficacy of testosterone supplementation in improving indices of urodynamic function (i.e., bladder, urethra, and sphincter function), assessed by urodynamic testing. These urodynamic measures include Valsava leak point pressure, urethral pressure profile, cystometry and electromyography. As an exploratory aim, the efficacy of testosterone treatment relative to placebo will be assessed using self-reported urinary symptoms assessed by the Urogenital Distress Inventory (UDI) and quality of life assessed by the Incontinence Impact Questionnaire (IIQ).

03

Conditions studied

  • Stress Urinary Incontinence
  • Menopause

Keywords

  • stress urinary incontinence
  • testosterone therapy
  • menopause
  • pelvic floor disorders
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women, age 60 years and older.
  • Medically documented pure stress urinary incontinence on physical exam or urodynamic testing.
  • Normal mammogram within the last 12 months
  • Endometrial thickness of ≤4 mm in women with an intact uterus assessed by endometrial ultrasound.
  • Ability and willingness to provide .

Exclusion criteria

Exclusion Criteria:

    • Medically documented urge or mixed urinary incontinence (stress and urge) on physical exam or urodynamic testing.

      • Participating in pelvic floor muscle training (PFMT) therapy currently or in the past 3 months
      • Previous pelvic surgery (i.e., hysterectomy, pelvic organ prolapse repair, mid-urethral sling placement, injection of urethral bulking agents) or radiation treatment to the pelvis.
      • History of ≥ Grade 3 pelvic organ prolapse
      • Neurologic disorder causing UI or bladder dysfunction (i.e., multiple sclerosis, Parkinson's disease, stroke, cerebral palsy, spinal cord injury)
      • Current urinary tract infection
      • History of breast or endometrial cancer
      • Use of systemic estrogen therapy in the past 3 months
      • Baseline hematocrit >48%, serum creatinine >2.5 mg/dL; >8.0%; >40 kg/m2
      • Uncontrolled hypertension defined as an average of two blood pressure readings of greater than 160/100.
      • Subjects who are on insulin therapy will be excluded.
      • Uncontrolled congestive heart failure
      • Myocardial infarction, acute coronary syndrome, revascularization surgery or stroke within 6 months
      • History of pulmonary embolism, deep vein thrombosis or a genetic thromboembolic disorder
      • History of bipolar disorder, schizophrenia or untreated major depression
      • Presence of metallic implants (pacemakers, aneurysm clips, etc.) that preclude the patient from undergoing MRI
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Testosterone

    Testosterone Cypionate 25-mg weekly by intramuscular injection

    Drug: Testosterone cypionate

  • Placebo comparator
    Placebo

    Placebo intramuscular injections weekly

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in pelvic floor muscle volume

    volume of levator ani muscles of the pelvic floor, assessed by magnetic resonance imaging (MRI)

    Time frame: 12 weeks

Secondary outcomes

  1. Change in abdominal leak point pressure

    abdominal leak point pressure will be measured by a urodynamic function study

    Time frame: 12 weeks

  2. Change in urine flow rate

    urine flow rate will be measured by urodynamic function a study

    Time frame: 12 weeks

  3. Change in bladder pressure

    bladder pressure will be measured during filling, storage and voiding by urodynamic study

    Time frame: 12 weeks

  4. Change in post void residual urine volume

    post void residual urine volume will be measured using bladder ultrasound

    Time frame: 12 weeks

  5. Change in urinary symptoms

    self-reported urinary symptoms will be assessed by the Urogenital Distress Inventory (UDI). Total score ranges from 6-24 with higher scores indicating higher severity of symptoms

    Time frame: 12 weeks

  6. Change in quality of life

    quality of life will be assessed by the Incontinence Impact Questionnaire (IIQ). Total score ranges from 0-21 with higher scores indicating worse impact on quality of life.

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 15 phase 2 interventional studies under Urinary Incontinence, Stress, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Nov 1, 2023
StartActual
Feb 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 1, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06111209
Responsible party
Shalendar Bhasin, MD (Principal Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 1, 2023
Start date
Feb 15, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

Grace Huang, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Testosterone 17 beta-cypionate

Start the discussion